Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Biogen Inc    BIIB


News SummaryMost relevantAll newsSector newsTweets 

Biogen Idec Inc. : Biogen Sees Positive Results From First Year of MS Treatment Study

share with twitter share with LinkedIn share with facebook
share via e-mail
03/20/2013 | 01:06pm CET
   By Saabira Chaudhuri 

Biogen Idec Inc. (BIIB) said it has seen positive results from the first year of a two-year late-stage study of its investigational candidate for a type of multiple sclerosis.

Biogen said results from its two-year pivotal Phase 3 "Advance" study of Plegridy, its investigational candidate for relapsing-remitting multiple sclerosis dosed once every two weeks or every four weeks, indicate that Plegridy significantly reduced multiple sclerosis disease activity, including relapses, disability progression and brain lesions, compared with placebo at one year.

"These full first-year results provide a more complete picture of Plegridy and its positive effects on the reduction of relapse, disability progression and lesion development," said Peter Calabresi, director at the Johns Hopkins Multiple Sclerosis Center. "These data suggest that, if approved, Plegridy may offer the benefit of a less frequent dosing schedule, which would be a meaningful advance for people living with multiple sclerosis."

Plegridy--also called peginterferon beta-1a--met the primary endpoint of reducing annualized relapse rate at one year by 36% compared with placebo. It also met its secondary endpoint, reducing the proportion of patients who relapsed by 39% compared with placebo. Additionally, it significantly reduced the number of gadolinium-enhancing lesions by 86% compared with placebo.

Biogen described Plegridy as a new molecular entity in which interferon beta-1a is pegylated to extend its half-life and prolong its exposure in the body, enabling study of a less-frequent dosing schedule. The investigational drug candidate is a member of the interferon class of treatments and, if approved, would be a new addition to this class, which often is used as a first-line treatment for multiple sclerosis.

The latest announcement comes after, in January, Biogen said data from a late-stage trial of Plegridy were positive. At the time, Biogen said the study's primary endpoint was met for both the two-week and four-week dose regimens. Results showed that Plegridy also met the secondary endpoints. It noted that with both dose regimens studied the risk-benefit profile of Plegridy appears to be favorable.

Also in January, Biogen reported its fourth-quarter earnings fell 2.7% as the biotechnology company's preparations to launch a new drug for multiple sclerosis increased expenses and masked revenue growth from its existing multiple sclerosis treatment.

Shares closed Tuesday at $175.61 and were inactive in recent premarket trading. The stock has risen 47% in the past 12 months.

Write to Saabira Chaudhuri at saabira.chaudhuri@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BIOGEN INC
01/17 BIOGEN FOURTH QUARTER AND YEAR END 2 : 00 am on January 26, 2017
01/17 SIEMENS HEALTHINEERS : and Biogen Announce Agreement to Jointly Develop New MRI ..
01/17DJBIOGEN : Reaches Settlement and License Agreement for MS Drug
01/17 BIOGEN : and Forward Pharma Agree to Enter into Settlement and License Agreement
01/12 BIOGEN : Spin-off Bioverativ Commences When-Issued Trading of Common Stock
01/05 BIOGEN : exercises option to enter into exclusive, worldwide License Agreement f..
01/02 New drug approvals fall to six-year low in 2016
2016 BIOGEN : Announces Effectiveness of Bioverativ Form 10 Registration Statement
2016 BIOGEN : and Spin-off Bioverativ will Present at the Goldman Sachs Healthcare CE..
2016 BIOGEN : Names Michel Vounatsos Chief Executive Officer
More news
Sector news : Biopharmaceuticals
11:15a GSK grabs Astra executive to replace pharma head
10:40aDJGLAXOSMITHKLINE : Global Pharmaceuticals President Abbas Hussain to Leave -- Upd..
08:48aDJBusiness Watch -- WSJ
08:28aDJGLAXOSMITHKLINE : Global Pharmaceuticals President Abbas Hussain to Leave
01/18DJCSL : Expects Higher Profits On Strong Immunoglobulin Sales -- Update
More sector news : Biopharmaceuticals
News from SeekingAlpha
01/18 BIOTECH FORUM DAILY DIGEST : Sector Gets 'Trumped' Again - Spotlight On Sucampo ..
01/18 Boehringer Ingelheim's marketing applications for Humira biosimilar under rev..
01/18 Biogen Windfall Reveals Europe's Best Capitalized And Most Mispriced Biotech
01/17 Siemens, Biogen to develop new MRI tools
01/17 Biogen to pay Forward Pharma $1.25B in patent infringement case related to MS..
Financials ($)
Sales 2016 11 524 M
EBIT 2016 6 046 M
Net income 2016 4 129 M
Debt 2016 578 M
Yield 2016 -
P/E ratio 2016 15,13
P/E ratio 2017 14,72
EV / Sales 2016 5,40x
EV / Sales 2017 5,09x
Capitalization 61 706 M
More Financials
Duration : Period :
Biogen Inc Technical Analysis Chart | BIIB | US09062X1037 | 4-Traders
Full-screen chart
Technical analysis trends BIOGEN INC
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 340 $
Spread / Average Target 20%
Consensus details
EPS Revisions
More Estimates Revisions
Michel Vounatsos Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Paul J. Clancy Chief Financial Officer & Executive Vice President
Alfred W. Sandrock Chief Medical Officer & Executive Vice President
Spyridon Artavanis-Tsakonas Chief Scientific Officer & Executive VP
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN INC0.01%61 706
CSL LIMITED-0.21%34 174
GRIFOLS SA1.59%12 987
More Results